Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Ovarian Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2Wilms Tumor 1Sarcoma 1Rhabdomyosarcoma 1Retroperitoneal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Peritoneal Cavity Cancer 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Mesothelioma, Malignant 1High Grade Serous Ovarian 1Gliosarcoma 1Gastrointestinal Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma 1Astrocytoma 1Appendiceal Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

Temozolomide 41Radiotherapy 15Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Bevacizumab 10Irinotecan 9Radiation 8Nivolumab 7Carmustine 7Specimen Handling 6Radiosurgery 6Carboplatin 6ribociclib 5O(6)-benzylguanine 5Imiquimod 5IL13-PE38 5Flucytosine 5Filgrastim 5Erlotinib Hydrochloride 5Cyclophosphamide 5Aminolevulinic Acid 5vandetanib 4sargramostim 4Topotecan 4Lomustine 4Imatinib Mesylate 4Etoposide 4Craniotomy 4vocimagene amiretrorepvec 3temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Glioma × Cytoreduction Surgical Procedures × Clear all
NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Columbia University

Phase 1 Completed
22 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02238496 2023-05-25

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Columbia University

Phase 1 Completed
10 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡